

Activating the patient's immune system to fight cancer

Redeye Fight Cancer Seminar

Stockholm 22 January



targovax

IMPORTANT NOTICE AND DISCLAIMER

This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of operations and the financial condition of Targovax. Such forward-looking statements reflect the current views of Targovax and are based on the information currently available to the company. Targovax cannot give any assurance as to the correctness of such statements.

There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. These factors include, among other things, risks or uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in connection with clinical trials or following commercialization of the company's products, and liability in connection therewith; risks relating to the company's freedom to operate (competitors patents) in respect of the products it develops; risks of non-approval of patents not yet granted and the company's ability to adequately protect its intellectual property and know-how; risks relating to obtaining regulatory approval and other regulatory risks relating to the development and future commercialization of the company's products; risks that research and development will not yield new products that achieve commercial success; risks relating to the company's ability to successfully commercialize and gain market acceptance for Targovax's products; risks relating to the future development of the pricing environment and/or regulations for pharmaceutical products; risks relating to the company's ability to secure additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency fluctuations; risks associated with technological development, growth management, general economic and business conditions; risks relating to the company's ability to retain key personnel; and risks relating to the impact of competition.





1

Introduction


2. ONCOS oncolytic virus program
3. Development pipeline

TARGOVAX AIMS TO ACTIVATE THE PATIENT'S IMMUNE SYSTEM TO FIGHT CANCER

Targovax focus




Two programs in clinical development, with an ONCOLYTIC VIRUS LEAD PRODUCT CANDIDATE



ONCOS
Oncolytic virus

Lead product candidate

- Genetically armed **adenovirus**
- Triggers production of T-cells targeting the **patient's specific tumor**
- 4 ongoing trials



TG
Neoantigen
vaccine

Pipeline product

- **Shared neoantigen**, therapeutic cancer vaccine
- Triggers production of T-cells targeting **mutant RAS cancers**
- 1 recently completed, 1 ongoing trial

Triggers patient-specific responses

No need for individualization


2

ONCOS oncolytic virus program

3. Development pipeline




ONCOS CLINICAL PROGRAM OVERVIEW





ONCOS CLINICAL PROGRAM OVERVIEW



COMPLETE RESPONSE IN MELANOMA PATIENT

advanced disease, refractory to both Yervoy and Keytruda



Baseline



Progression on Keytruda®

Week 3



*Visible tumor regression
after 3x ONCOS-102
injections*

Week 9



*Complete response (CR) after
3x ONCOS-102 injections
& 2 Keytruda® infusions*

ONCOS-102 + KEYTRUDA MELANOMA TRIAL

one patient had a complete response by week 9

1

Safety


- ✓ **First safety review completed with no concerns**
- ✓ **ONCOS-102 and KEYTRUDA® combination is well-tolerated**



2

Innate immune activation


- ✓ **Systemic increase of pro-inflammatory cytokines (6/6 patients)**
- ✓ **All patients develop fever**



3

Adaptive immune activation

- ✓ **Increase in tumor T-cell infiltration (TILs, 3/4 patients)**
- ✓ **Tumor-specific T cells in 2/4 patients**
- ✓ **Abscopal immune response in one patient**



4

Efficacy

- ✓ **Complete response in 1/6 patients (very rare)**
- ✓ **Transient regression in 3 patients**
- ✓ **Associated with level of immune activation**




SECOND DOSE COHORT TO BE INITIATED

up to 12 additional patients who will receive 12 ONCOS-102 injections


From:

1st dose cohort
3x ONCOS-102
injections




To:

2nd dose cohort
12x ONCOS-102
injections



PRECLINICAL DEVELOPEMENT NEXT GENERATION ONCOLYTIC VIRUSES



- Adenoviruses – same backbone as ONCOS-102
- Targets and transgenes undisclosed
- Unique modalities that affects the micro tumor environment and the immune system in different ways



ACTIVATING THE PATIENT'S IMMUNE SYSTEM

to fight cancer

ONCOS-102: lead product

Strong single agent data
Several upcoming data points

TG: clinical effect in pancreas

First cancer vaccine to show
immune activation against a
driver mutation

Ideal combination product

Innovative pipeline

Next generation
viruses in testing